Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Soria SC, Plummer R, Soto A, Massard C, Calvert H, Prados R, Angevin E, Jones C, de las Heras B

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Year of Conference: 2008

Pages: 57-57

ISSN: 1359-6349

Publisher: European Journal of Cancer Supplements: Pergamon

URL: http://dx.doi.org/10.1016/S1359-6349(08)72111-6

DOI: 10.1016/S1359-6349(08)72111-6

Notes: Poster no. 179

ePrints